Literature DB >> 25497383

Acceptability and feasibility of phone follow-up with a semiquantitative urine pregnancy test after medical abortion in Moldova and Uzbekistan.

Ingrida Platais1, Tamar Tsereteli2, Rodica Comendant3, Dilfuza Kurbanbekova4, Beverly Winikoff5.   

Abstract

OBJECTIVE: To evaluate the feasibility and acceptability of phone follow-up with a home semiquantitative pregnancy test and standardized checklist, and compare the alternative method of follow-up with in-clinic follow-up after medical abortion. STUDY
DESIGN: Two thousand four hundred women undergoing medical abortion with mifepristone and misoprostol in Moldova and Uzbekistan were randomized to phone or clinic follow-up. All women in the clinic group returned to the clinic 2 weeks later. Women randomized to phone follow-up used a semiquantitative pregnancy test at the initial visit and repeated the test at home 2 weeks later when they also filled out a symptom checklist. Women were called at 2 weeks to review the test results and checklist. Participants who screened "positive" were referred to clinic to verify abortion completion.
RESULTS: Most women in the phone group were successfully contacted on the phone (97.6%). Staff were unable to contact one woman in the phone follow-up group, and all women in clinic group returned to the clinic. The ongoing pregnancy rate was similar in both groups (0.4-0.6%), and the semiquantitative pregnancy test identified all ongoing pregnancies in the phone follow-up group. Women in the phone group found the test and checklist easy to use, and most (76.1%) preferred phone follow-up in the future. Overall, 92.8% of women in the phone group did not undergo in-clinic follow-up.
CONCLUSION: Phone follow-up with a semiquantitative urine pregnancy test and symptom checklist is a feasible and a highly effective approach in identifying ongoing pregnancy after medical abortion. IMPLICATIONS: The semiquantitative pregnancy test can make home follow-up after medical abortion possible for many women and provide reassurance that ongoing pregnancies will be detected.
Copyright © 2015 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Checklist; Human chorionic gonadotropin; Mifepristone; Misoprostol; Symptoms

Mesh:

Year:  2014        PMID: 25497383     DOI: 10.1016/j.contraception.2014.11.004

Source DB:  PubMed          Journal:  Contraception        ISSN: 0010-7824            Impact factor:   3.375


  5 in total

1.  Self-administered multi-level pregnancy tests in simplified follow-up of medical abortion in Tunisia.

Authors:  Rasha Dabash; Tara Shochet; Selma Hajri; Héla Chelli; Anne-Emmanuele Hassairi; Douha Haleb; Hayet Labassi; Ezzedine Sfar; Fatma Temimi; Leah Koenig; Beverly Winikoff
Journal:  BMC Womens Health       Date:  2016-07-30       Impact factor: 2.809

2.  A harm-reduction model of abortion counseling about misoprostol use in Peru with telephone and in-person follow-up: A cohort study.

Authors:  Daniel Grossman; Sarah E Baum; Denitza Andjelic; Carrie Tatum; Guadalupe Torres; Liza Fuentes; Jennifer Friedman
Journal:  PLoS One       Date:  2018-01-10       Impact factor: 3.240

3.  Results of a pilot study in the U.S. and Vietnam to assess the utility and acceptability of a multi-level pregnancy test (MLPT) for home monitoring of hCG trends after assisted reproduction.

Authors:  Tara Shochet; Ioanna A Comstock; Nguyen Thi Nhu Ngoc; Lynn M Westphal; Wendy R Sheldon; Ly Thai Loc; Jennifer Blum; Beverly Winikoff; Paul D Blumenthal
Journal:  BMC Womens Health       Date:  2017-08-22       Impact factor: 2.809

4.  Is self-assessment of medical abortion using a low-sensitivity pregnancy test combined with a checklist and phone text messages feasible in South African primary healthcare settings? A randomized trial.

Authors:  Deborah Constant; Jane Harries; Kristen Daskilewicz; Landon Myer; Kristina Gemzell-Danielsson
Journal:  PLoS One       Date:  2017-06-22       Impact factor: 3.240

5.  Self-testing for pregnancy: a systematic review and meta-analysis.

Authors:  Caitlin E Kennedy; Ping Teresa Yeh; Karima Gholbzouri; Manjulaa Narasimhan
Journal:  BMJ Open       Date:  2022-02-28       Impact factor: 2.692

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.